Page last updated: 2024-12-06

4,5-dimethyl-3-hydroxy-2(5h)-furanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID62835
CHEMBL ID3185688
CHEBI ID67890
SCHEMBL ID246671
MeSH IDM0153881

Synonyms (50)

Synonym
2(5h)-furanone, 3-hydroxy-4,5-dimethyl-
sotolone
2,3-dimethyl-4-hydroxy-2,5-dihydrofuran-5-one
3-hydroxy-4,5-dimethylfuran-2(5h)-one
4,5-dimethyl-3-hydroxy-2(5h)-furanone
3-hydroxy-4,5-dimethyl-2(5h)-furanone
2-hydroxy-3,4-dimethyl-2-buten-1,4-olide
2-hydroxy-3-methyl-2-penten-4-olide
fema no. 3634
einecs 249-136-4
4,5-dimethyl-3-hydroxy-2,5-dihydrofuran-2-one
4,5-dimethyl-3-hydroxy-2,5-dihydro-2-furanone
4,5-dimethyl-3-hydroxy-2,5-dihydrofuran-2-one, >=97%, fg
sotolon
28664-35-9
4-hydroxy-2,3-dimethyl-2h-furan-5-one
D1851
cas-28664-35-9
dtxsid4047674 ,
tox21_302500
NCGC00256815-01
dtxcid2027674
A819527
2,3-dimethyl-4-oxidanyl-2h-furan-5-one
CHEBI:67890 ,
t62rl2negw ,
unii-t62rl2negw
caramel furanone
FT-0617204
AKOS015915483
SCHEMBL246671
4,5-dimethyl-3-hydroxy-2,5-dihydro-2-furanone [fhfi]
sautalone
W-107036
furan-2(5h)-one, 3-hydroxy-4,5-dimethyl-
UNYNVICDCJHOPO-UHFFFAOYSA-N
3-hydroxy-4,5-dimethyl-5h-furan-2-one
CHEMBL3185688
3-hydroxy-4,5-dimethyl-2,5-dihydrofuran-2-one
mfcd00059957
4,5-dimethyl-3-hydroxy-2,5-dihydrofuran-2-one, analytical standard
3,4-dimethyl-2-hydroxy-2-butan-1,4-olide
3-hydroxy-4,5-dimethyl-furan-2(5h)-one
DS-4143
Q421173
D82247
SB60893
EN300-7418981
CS-0035224
D5850
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
butenolideA gamma-lactone that consists of a 2-furanone skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Olfactory Signaling Pathway8028
Sensory Perception21568

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.02170.006038.004119,952.5996AID1159521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (11.43)18.2507
2000's12 (34.29)29.6817
2010's14 (40.00)24.3611
2020's5 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.30 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (2.78%)4.05%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]